Ranibizumab ELISA(measures Total Drug - Free, Bound Or Partially Bound) (LUCENTIS)

Ranibizumab (LUCENTIS) ELISA for determination of Ranibizumab (measures total drug - free, bound or partially bound) in human serum, plasma and cell culture supernatant.

Intended Use:
The KRIBIOLISA™ Ranibizumab (Lucentis™) ELISA is used as an analytical tool for quantitative determination
of Ranibizumab in serum and plasma. The kit measures total drug (free, bound or partially bound).
 

Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Ranibizumab are
pre-coated onto microwells. HRP Conjugate, Samples / Standards are pipetted into microwells and human
Ranibizumab present in the sample are bound by the capture antibody. After washing microwells in order to
remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color
develops proportionally to the amount of Ranibizumab in the sample. Color development is then stopped by
addition of stop solution. Absorbance is measured at 450 nm.